Morinda officinalis is an important traditional tonic herbal medicine. In the present study, we found that crude polysaccharides extracted from M. officinalis, named MO90, could significantly increase the bone mineral density (BMD) of the whole femur, distal femur, and proximal femur in ovariectomized (OVX) rats. In addition, MO90 decreased the level of bone turnover markers and prevented the deterioration of trabecular microarchitecture. To investigate the fractions responsible for anti-osteoporosis activity, one novel inulin-type fructan, MOW90-1, was isolated from MOP90. Structural analysis indicated that MOW90-1 consists of a backbone of (2→1)-linked-β-D-Fruf, and is terminated with (1→)-linked-α-D-Glcp and (2→)-linked-β-D-Fruf. Furthermore, an in vitro anti-osteoporosis assay indicated that MOW90-1 promoted proliferation, differentiation, and mineralization of MC3T3-E1 cells by up-regulating the expression of runt-related transcription factor 2, osterix, osteopontin, and osteocalcin. In conclusion, our studies provide supporting evidence for future use of this novel M. officinalis fructan as a key nutrient of health products.
Keywords: Anti-osteoporosis; Morinda officinalis; Polysaccharides.
Copyright © 2019 Elsevier B.V. All rights reserved.